Eli Lilly reported a 55.5% revenue increase in Q1, driven by strong sales of Mounjaro and Zepbound totaling $12.8 billion. Despite this growth, shares have only risen slightly due to pricing pressures and charges from acquisitions and litigation. The company raised its full-year revenue guidance to $82-$85 billion and analysts see potential for a 12% stock upside, with some bullish forecasts targeting up to $1,500 per share by 2028. Achieving this would depend on successful international expansion of obesity drugs and continued earnings growth amid regulatory risks.
Major investors are increasingly focusing on AI-driven biology and longevity, with startups like NewLimit tripling in value. While many of these startups remain private, NVIDIA and Eli Lilly stand out as the main public companies involved, partnering...
Wells Fargo's economist forecasts GLP-1 weight-loss drugs like Ozempic and Mounjaro will reach about 90 million prescriptions, rivaling statins. This trend is driving demand for high-protein, low-volume foods suited for appetite-suppressed patients, ...
In the first half of 2026, smart beta strategies showed mixed results, with momentum and low-volatility funds lagging, while dividend growth funds struggled due to rising yields. However, funds emphasizing companies with strong free cash flow and hig...
Eli Lilly announced positive Phase 3 BRUIN CLL-322 study results showing that adding pirtobrutinib to venetoclax and rituximab significantly improves progression-free survival in patients with relapsed or refractory chronic lymphocytic leukemia (CLL)...
A list of the top 25 high-growth dividend stocks for June 2026 highlights quality companies trading about 30% below intrinsic value, with an average dividend yield of 1.50% and a five-year dividend growth rate of 17.61%. The basket is estimated to de...
